All Companies
Company Search:
My Pulse
Profile:
Create New Profile
Choose Companies
Portfolios:
Create/Edit
or select by:
Discover Business Solutions
Subscribe to PulsePro
Refer a Friend
batchsize=10; event_count=2; year=2010; month=3; day=16; hour=19; minute=31; second=55;
event_date=2009-11-17 07:33:53; sort_date=40134.315197;
Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
StreetInsider.com - New Coverage -
Nov 17, 2009
Antares Pharma Incorporated
(AIS) -
Merriman Curhan Ford
Merriman
analyst says, "We believe
Antares
represents a strong value play in the drug delivery space.
Merriman
analyst says, "We believe
Antares
represents a strong value play in the drug delivery space.
Share:
<span class="sent"><span class="analyst">Merriman</span> analyst says, "We believe <span class="company">Antares</span> represents a strong value play in the drug delivery space. </span>
Tweet this
event_date=2009-06-29 11:56:19; sort_date=39993.497442;
Teva, Antares get FDA nod for needle-free device
Reuters India -
Jun 29, 2009
Antares Pharma Incorporated
(AIS) -
Matthew Kaplan
at
Ladenburg, Thalmann & Co.
"This is an important validation of the Teva partnership, which is the primary driver of our valuation and excitement about
Antares
stock," Ladenburg Thalmann analyst
Matthew Kaplan
said by phone.
"This is an important validation of the Teva partnership, which is the primary driver of our valuation and excitement about
Antares
stock," Ladenburg Thalmann analyst
Matthew Kaplan
said by phone.
Shares of
Antares
rose as much as 58 percent to a new year high of $1.14, before paring some gains to trade up at $1.02 in morning trade Monday on the American Stock Exchange.
Share:
<span class="sent">"This is an important validation of the Teva partnership, which is the primary driver of our valuation and excitement about <span class="company">Antares</span> stock," Ladenburg Thalmann analyst <span class="analyst">Matthew Kaplan</span> said by phone. </span> Shares of <span class="company">Antares</span> rose as much as 58 percent to a new year high of $1.14, before paring some gains to trade up at $1.02 in morning trade Monday on the American Stock Exchange. ...<span class="sent">"This is an important validation of the Teva partnership, which is the primary driver of our valuation and excitement about <span class="company">Antares</span> stock," Ladenburg Thalmann analyst <span class="analyst">Matthew Kaplan</span> said by phone. </span> Shares of <span class="company">Antares</span> rose as much as 58 percent to a new year high of $1.14, before paring some gains to trade up at $1.02 in morning trade Monday on the American Stock Exchange.
Tweet this
more
Create New Profile
Tweet this